Two studies of commercially available biomarkers of synucleinopathies have reached sharply different conclusions on their reliability, according to the findings from two abstracts presented at the AAN Annual Meeting, held in Denver in April.
Two Studies, Two Different Conclusions on Biomarkers for Lewy Body Dementia
View Content